J? Hepatology: Analysis of the efficacy of bear deoxycholic acid (UDCA) in the treatment of primary bile-based bilebaritis.

Relapses of primary bile-based bile dulineitis (PBC) after background and target liver transplantation (LT) are common and can impair liver transplants and patient survival time.
deoxycholic acid (UDCA) is currently the standard treatment for PBC.
study aims to investigate the effects of preventive use of UDCA on the rate and long-term consequences of PBC recurrence after LT.
1983-2017, researchers conducted retrospective queue studies on 780 patients with PBC liver transplants in 16 research centers (9 countries), with an average follow-up of 11 years.
, 190 people were treated with preventive UDCA (10-15 mg / kg / day).
outcomes were histological manifestations of PBC recurrence, liver-related deaths and all-cause deaths.
the association between preventive UDCA and prognosm, using the multivariate-adjusted Cox model and the Restricted Average Time to Live (RMST) model.
results Although the recurrence of PBC significantly shortens the lifetime of liver grafts and patients, the risk of prophylactic use of UDCA and PBC recurrence is reduced. 0.0001), loss of graft (aHR 0.33; 95% CI 0.13-0.82; p .lt; 0.0001), liver-related death (aHR 0.46; 95% CI 0.22-0.98; p .lt; 0.05) is related to all-cause death (aHR 0.69; 95% CI 0.49-0.96; p .lt; 0.05).
in the RMST analysis, preventive use of UDCA can achieve a lifetime of 2.26 years (95% CI 1.28-3.25) over 20 years.
exposure to cyclosporine instead of thokmos has a complementary protective effect of preventive UDCA, thereby reducing the cumulative rate of PBC recurrence and all-cause death.
concluded that the preventive use of UDCA after PBC liver transplantation was associated with a decrease in the risk of disease recurrence, liver graft damage and death.
combined use of cyclosporine and preventive UDCA to minimize the risk of PBC recurrence and death.
.